FDA Accepts Supplement Application for Celecoxib by Alembic
The FDA has accepted a supplemental application for Celecoxib (ANDA204519) submitted by Alembic.
Therapeutic Area
Therapeutic area intelligence for COX-2 Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.